跳至主要内容
临床试验/NCT01225718
NCT01225718已完成不适用

Ceftriaxone in Non-neutropenic Fever

Vanderbilt University Medical Center1 个研究点 分布在 1 个国家目标入组 463 人开始时间: 2010年8月最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
入组人数
463
试验地点
1
主要终点
Incidence of catheter-associated blood stream infections from all episodes of non-neutropenic fever in pediatric oncology, Langerhans cell histiocytosis or Hemophagocytic lymphohistiocytosis patients diagnosed and treated at Vanderbilt

研究概览

简要总结

This is a retrospective chart review of all patients cared for at Monroe Carell Jr. Children's Hospital at Vanderbilt including the following:

  • patients between 2007-2009 with malignancy, Langerhans cell histiocytosis (LCH) or hemophagocytic lymphohistiocytosis (HLH) and a central venous catheter who were under 23 years of age at time of diagnosis in order to ascertain the associated symptoms, management and outcome of all episodes of non-neutropenic fever.
  • to identify a subset of low-risk patients that can be safely managed without use of empiric antibiotics.

研究设计

研究类型
Observational
观察模型
Case Only
时间视角
Retrospective

入排标准

年龄范围
— 至 22 Years(Child, Adult)
性别
All
接受健康志愿者

入选标准

  • Diagnosed with malignancy, Langerhans cell histiocytosis,or hemophagocytic lymphohistiocytosis from 2007 through 2010
  • Under 23 years at time of diagnosis of malignancy, Langerhans cell histiocytosis,or hemophagocytic lymphohistiocytosis
  • Treated at Monroe Carell Jr. Children's Hospital at Vanderbilt for aforementioned diagnosis from 2007 through 2012
  • While on immunosuppressive therapy with a central venous line in place had at least one documented episode of fever (defined as ≥ 38.0°Celsius orally for over 30 minutes or ≥ 38.3°Celsius orally x1).

排除标准

  • Does not meet all inclusion criteria as stated above

结局指标

主要结局

Incidence of catheter-associated blood stream infections from all episodes of non-neutropenic fever in pediatric oncology, Langerhans cell histiocytosis or Hemophagocytic lymphohistiocytosis patients diagnosed and treated at Vanderbilt

时间窗: 12 months

次要结局

  • Identify risk factors associated with increased risk for catheter-associated blood stream infections in non-neutropenic pediatric oncology and histiocytosis patients with unexplained fever by collecting data for all eligible medical records.(12 months)
  • Effectiveness of administering empiric cefepime or ceftriaxone in a non-neutropenic oncology or histiocytic patient is estimated, using available microbiologic and antimicrobial susceptibility data from blood cultures(12 months)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Adam Esbenshade

Assistant Professor of Pediatrics

Vanderbilt University Medical Center

研究点 (1)

Loading locations...

相似试验

Ceftriaxone in Non-neutropenic Fever | 临床试验